Victory Capital Management’s Ascendis Pharma A/S ASND Stock Holding History

Victory Capital Management’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.35M	Sell	27,540 -3,230	-10%	-$755K	﹤0.01%	1246
2026 Q1	$7.04M	Sell	30,770 -12,420	-29%	-$2.78M	﹤0.01%	1204
2025 Q4	$9.21M	Sell	43,190 -165,741	-79%	-$34.2M	0.01%	1085
2025 Q3	$41.5M	Sell	208,931 -10,187	-5%	-$1.9M	0.02%	631
2025 Q2	$37.8M	Buy	219,118 +94,192	+75%	+$15.3M	0.02%	650
2025 Q1	$19.5M	Sell	124,926 -6,427	-5%	-$918K	0.02%	819
2024 Q4	$18.1M	Sell	131,353 -2,505	-2%	-$329K	0.02%	886
2024 Q3	$20M	Sell	133,858 -551	-0.4%	-$74.4K	0.02%	847
2024 Q2	$18.3M	Sell	134,409 -155	-0.1%	-$21.1K	0.02%	841
2024 Q1	$20.3M	Buy	+134,564	New	+$19.2M	0.02%	813
2021 Q2	–	Sell	-518,396	Closed	-$66.8M	–	2745
2021 Q1	$66.8M	Buy	518,396 +10,638	+2%	+$1.62M	0.07%	422
2020 Q4	$84.7M	Buy	507,758 +142,341	+39%	+$23.5M	0.09%	319
2020 Q3	$56.4M	Sell	365,417 -33,021	-8%	-$4.75M	0.07%	424
2020 Q2	$58.9M	Sell	398,438 -3,088	-0.8%	-$424K	0.08%	369
2020 Q1	$45.2M	Sell	401,526 -143,439	-26%	-$18.6M	0.08%	372
2019 Q4	$75.8M	Buy	544,965 +106,451	+24%	+$11.8M	0.09%	315
2019 Q3	$42.2M	Buy	438,514 +97,606	+29%	+$10.9M	0.05%	515
2019 Q2	$39.3M	Buy	340,908 +18,190	+6%	+$2.18M	0.08%	387
2019 Q1	$38M	Buy	322,718 +299,400	+1,284%	+$26.2M	0.09%	366
2018 Q4	$1.46M	Sell	23,318 -420	-2%	-$26.4K	﹤0.01%	1115
2018 Q3	$1.68M	Sell	23,738 -1,240	-5%	-$85.4K	﹤0.01%	1136
2018 Q2	$1.66M	Sell	24,978 -1,360	-5%	-$89.4K	﹤0.01%	1116
2018 Q1	$1.72M	Buy	26,338 +8,970	+52%	+$504K	﹤0.01%	1108
2017 Q4	$696K	Buy	17,368 +12,010	+224%	+$437K	﹤0.01%	1288
2017 Q3	$194K	Buy	+5,358	New	+$154K	﹤0.01%	1541
2017 Q2	–	Sell	-5,158	Closed	-$144K	–	1809
2017 Q1	$144K	Buy	+5,158	New	+$130K	﹤0.01%	1521

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Victory Capital Management's ASND Position: Q2 2026 in Review

Victory Capital Management reduced its Ascendis Pharma A/S (ASND) stake by 10% in Q2 2026, selling an estimated $755K and leaving 27,540 shares worth $7.35M. The position accounts for ﹤0.01% of the portfolio, ranked #1246.

Victory Capital Management first reported a position in ASND in Q1 2017 and has held it in 26 quarters since. The position peaked at $84.7M in Q4 2020. 312 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Victory Capital Management held 27,540 shares of Ascendis Pharma A/S worth $7.35M as of Q2 2026.
Victory Capital Management sold 3,230 Ascendis Pharma A/S shares in Q2 2026, an estimated $755K.
Ascendis Pharma A/S made up ﹤0.01% of Victory Capital Management's portfolio in Q2 2026, its #1246 holding.
Victory Capital Management first reported a position in Ascendis Pharma A/S in Q1 2017 and has held it in 26 quarters since.
Victory Capital Management's Ascendis Pharma A/S position peaked at $84.7M in Q4 2020.
312 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Victory Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.